Unlock stock picks and a broker-level newsfeed that powers Wall Street.

NasdaqCM - Nasdaq Real Time Price USD

VYNE Therapeutics Inc. (VYNE)

1.8400
-0.0200
(-1.08%)
At close: April 23 at 4:00:00 PM EDT
Currency in USD All numbers in thousands
Download
Breakdown
TTM
12/31/2024
12/31/2023
12/31/2022
12/31/2021
Total Revenue
501
501
424
477
931
Cost of Revenue
--
--
--
--
3,348
Gross Profit
--
--
--
--
11,407
Operating Expense
44,138
44,138
29,682
34,772
39,842
Operating Income
-43,637
-43,637
-29,258
-34,295
-38,911
Net Non Operating Interest Income Expense
--
--
--
--
-5,610
Other Income Expense
3,834
3,834
1,386
363
-135
Pretax Income
-39,803
-39,803
-27,872
-33,932
-44,656
Tax Provision
4
4
--
13
-448
Net Income Common Stockholders
-39,834
-39,834
-28,452
-23,210
-73,329
Diluted NI Available to Com Stockholders
-39,834
-39,834
-28,452
-23,210
-73,329
Basic EPS
-0.93
-0.93
-2.78
-7.28
-25.56
Diluted EPS
-0.93
-0.93
-2.78
-7.28
-25.56
Basic Average Shares
42,589
42,589
10,273
3,186
2,859.3880
Diluted Average Shares
42,589
42,589
10,273
3,186
2,859.3880
Total Operating Income as Reported
-43,637
-43,637
-29,258
-34,295
-38,911
Total Expenses
44,138
44,138
29,682
34,772
39,842
Net Income from Continuing & Discontinued Operation
-39,834
-39,834
-28,452
-23,210
-73,329
Normalized Income
-39,807
-39,807
-27,872
-33,945
-44,208
Interest Expense
--
--
--
--
5,610
Net Interest Income
--
--
--
--
-5,610
EBIT
-43,637
-43,637
-29,258
-34,295
-39,046
EBITDA
-43,633
-43,633
-29,258
-34,223
-38,937
Reconciled Cost of Revenue
--
--
--
--
3,348
Reconciled Depreciation
4
4
--
72
109
Net Income from Continuing Operation Net Minority Interest
-39,807
-39,807
-27,872
-33,945
-44,208
Normalized EBITDA
-43,633
-43,633
-29,258
-34,223
-38,937
Tax Rate for Calcs
0.0002
0.0002
--
0.0002
0
12/31/2021 - 1/25/2018

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

ATXI Avenue Therapeutics, Inc.
0.2580
-4.44%
 
ELTX Elicio Therapeutics, Inc.
5.22
+3.37%
 
ERNA Ernexa Therapeutics Inc.
0.1938
+5.21%
 
ELVN Enliven Therapeutics, Inc.
17.77
-1.11%
 
GLYC GlycoMimetics, Inc.
0.2387
+4.69%
 
NTHI NeOnc Technologies Holdings, Inc. Common Stock
5.88
-2.00%
 
HTD.MU Corcept Therapeutics Inc
60.20
+5.73%
 
BT3.BE Lineage Cell Therapeutics Inc
0.4020
+8.06%
 
7AY1.F Actinium Pharmaceuticals, Inc.
1.1160
-6.92%
 
HQ1.MU Oruka Therapeutics Inc. R
9.15
+0.55%